Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus

Arthritis Research and Therapy

Volumn 14, Issue 6, 2012, Pages

  Hutcheson, Jack ^a   Vanarsa, Kamala ^a   Bashmakov, Anna ^a   Grewal, Simer ^a   Sajitharan, Deena ^a   Chang, Betty Y ^b   Buggy, Joseph J ^b   Zhou, Xin J ^a   Du, Yong ^a   Satterthwaite, Anne B ^a   Mohan, Chandra ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b PHARMACYCLICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; IBRUTINIB; AGAMMAGLOBULINAEMIA TYROSINE KINASE; AUTOANTIBODY; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CELL ACTIVITY; CELL TYPE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMORAL IMMUNITY; LEUKOCYTE ACTIVATION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PHENOTYPE; SIGNAL TRANSDUCTION; SPLENOMEGALY; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CONGENIC STRAIN; DRUG EFFECTS; FEMALE; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; KIDNEY; LUPUS NEPHRITIS; LYMPHOCYTE; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; LYMPHOCYTES; MALE; MICE, CONGENIC; MICE, INBRED C57BL; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION; SPLENOMEGALY; TREATMENT OUTCOME;

EID: 84868470425     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4086     Document Type: Article

References (58)

1. Iwaki S, Tkaczyk C, Satterthwaite AB, Halcomb K, Beaven MA, Metcalfe DD, Gilfillan AM. Btk plays a crucial role in the amplification of Fc epsilonRI-mediated mast cell activation by kit. J Biol Chem 2005, 280:40261-40270. 10.1074/jbc.M506063200, 16176929.
2. Mueller H, Stadtmann A, Van Aken H, Hirsch E, Wang D, Ley K, Zarbock A. Tyrosine kinase Btk regulates E-selectin-mediated integrin activation and neutrophil recruitment by controlling phospholipase C (PLC) gamma2 and PI3Kgamma pathways. Blood 2010, 115:3118-3127. 10.1182/blood-2009-11-254185, 2858472, 20167705.
3. Fiedler K, Sindrilaru A, Terszowski G, Kokai E, Feyerabend TB, Bullinger L, Rodewald HR, Brunner C. Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia. Blood 2011, 117:1329-1339. 10.1182/blood-2010-04-281170, 21063022.
4. Melcher M, Unger B, Schmidt U, Rajantie IA, Alitalo K, Ellmeier W. Essential roles for the Tec family kinases Tec and Btk in M-CSF receptor signaling pathways that regulate macrophage survival. J Immunol 2008, 180:8048-8056. 3001193, 18523268.
5. Vijayan V, Baumgart-Vogt E, Naidu S, Qian G, Immenschuh S. Bruton's tyrosine kinase is required for TLR-dependent heme oxygenase-1 gene activation via Nrf2 in macrophages. J Immunol 2011, 187:817-827. 10.4049/jimmunol.1003631, 21677132.
6. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62:222-233. 10.1002/art.27233, 20039413.
7. Petro JB, Rahman SM, Ballard DW, Khan WN. Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement. J Exp Med 2000, 191:1745-1754. 10.1084/jem.191.10.1745, 2193161, 10811867.
8. Bajpai UD, Zhang K, Teutsch M, Sen R, Wortis HH. Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation. J Exp Med 2000, 191:1735-1744. 10.1084/jem.191.10.1735, 2193152, 10811866.
9. Mohamed AJ, Yu L, Backesjo CM, Vargas L, Faryal R, Aints A, Christensson B, Berglof A, Vihinen M, Nore BF, Smith CI. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 2009, 228:58-73. 10.1111/j.1600-065X.2008.00741.x, 19290921.
10. Seldin MF, Reeves JP, Scribner CL, Roths JB, Davidson WF, Morse HC, Steinberg AD. Effect of xid on autoimmune C3H-gld/gld mice. Cell Immunol 1987, 107:249-255. 10.1016/0008-8749(87)90284-X, 3555848.
11. Steinberg BJ, Smathers PA, Frederiksen K, Steinberg AD. Ability of the xid gene to prevent autoimmunity in (NZB × NZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA. J Clin Invest 1982, 70:587-597. 10.1172/JCI110651, 370260, 6980900.
12. Satterthwaite AB, Lowell CA, Khan WN, Sideras P, Alt FW, Witte ON. Independent and opposing roles for Btk and lyn in B and myeloid signaling pathways. J Exp Med 1998, 188:833-844. 10.1084/jem.188.5.833, 2213392, 9730885.
13. Kersseboom R, Kil L, Flierman R, van der Zee M, Dingjan GM, Middendorp S, Maas A, Hendriks RW. Constitutive activation of Bruton's tyrosine kinase induces the formation of autoreactive IgM plasma cells. Eur J Immunol 2010, 40:2643-2654. 10.1002/eji.201040521, 20623551.
14. Kil LP, de Bruijn MJ, van Nimwegen M, Corneth OB, van Hamburg JP, Dingjan GM, Thaiss F, Rimmelzwaan GF, Elewaut D, Delsing D, van Loo PF, Hendriks RW. Btk levels set the threshold for B cell activation and negative selection of autoreactive B cells in mice. Blood 2012, 119:3744-3756. 10.1182/blood-2011-12-397919, 22383797.
15. Whyburn LR, Halcomb KE, Contreras CM, Lowell CA, Witte ON, Satterthwaite AB. Reduced dosage of Bruton's tyrosine kinase uncouples B cell hyperresponsiveness from autoimmunity in lyn-/- mice. J Immunol 2003, 171:1850-1858.
16. Jansson L, Holmdahl R. Genes on the X chromosome affect development of collagen-induced arthritis in mice. Clin Exp Immunol 1993, 94:459-465. 1534441, 8252807.
17. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010, 107:13075-13080. 10.1073/pnas.1004594107, 2919935, 20615965.
18. Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ, Carano RA, Darrow J, Davies DR, DeForge LE, Diehl L, Ferrando R, Gallion SL, Giannetti AM, Gribling P, Hurez V, Hymowitz SG, Jones R, Kropf JE, Lee WP, Maciejewski PM, Mitchell SA, Rong H, Staker BL, Whitney JA, Yeh S, Young WB, Yu C, Zhang J, Reif K, et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol 7:41-50.
19. Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011, 117:6287-6296. 10.1182/blood-2011-01-328484, 3122947, 21422473.
20. Chang BY, Huang MM, Francesco M, Chen J, Sokolove J, Magadala P, Robinson WH, Buggy JJ. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther 2011, 13:R115. 10.1186/ar3400, 3239353, 21752263.
21. Rudofsky UH, Evans BD, Balaban SL, Mottironi VD, Gabrielsen AE. Differences in expression of lupus nephritis in New Zealand mixed H-2z homozygous inbred strains of mice derived from New Zealand black and New Zealand white mice. Origins and initial characterization. Lab Invest 1993, 68:419-426.
22. Morel L, Rudofsky UH, Longmate JA, Schiffenbauer J, Wakeland EK. Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity 1994, 1:219-229. 10.1016/1074-7613(94)90100-7, 7889410.
23. Mohan C, Alas E, Morel L, Yang P, Wakeland EK. Genetic dissection of SLE pathogenesis. Sle1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosomes. J Clin Invest 1998, 101:1362-1372. 508713, 9525978.
24. Sobel ES, Satoh M, Chen Y, Wakeland EK, Morel L. The major murine systemic lupus erythematosus susceptibility locus Sle1 results in abnormal functions of both B and T cells. J Immunol 2002, 169:2694-2700.
25. Mohan C, Yu Y, Morel L, Yang P, Wakeland EK. Genetic dissection of Sle pathogenesis: Sle3 on murine chromosome 7 impacts T cell activation, differentiation, and cell death. J Immunol 1999, 162:6492-6502.
26. Zhu J, Liu X, Xie C, Yan M, Yu Y, Sobel ES, Wakeland EK, Mohan C. T cell hyperactivity in lupus as a consequence of hyperstimulatory antigen-presenting cells. J Clin Invest 2005, 115:1869-1878. 10.1172/JCI23049, 1143586, 15951839.
27. Mehrad B, Park SJ, Akangire G, Standiford TJ, Wu T, Zhu J, Mohan C. The lupus-susceptibility locus, Sle3, mediates enhanced resistance to bacterial infections. J Immunol 2006, 176:3233-3239.
28. Mohan C, Morel L, Yang P, Watanabe H, Croker B, Gilkeson G, Wakeland EK. Genetic dissection of lupus pathogenesis: a recipe for nephrophilic autoantibodies. J Clin Invest 1999, 103:1685-1695. 10.1172/JCI5827, 408382, 10377175.
29. O'Brien S, Burger JA, Blum KA, Furman RR, Coutre SE, Sharman J, Flinn IW, Grant B, Heerema NA, Johnson AJ, Navarro T, Holmgren E, Hedrick E, Byrd JC. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Follow-up of a phase Ib/II study. 53rd Annual Meeting of the American Society of Hematology: December 13, 2011 2011, Blood (ASH Annual Meeting Abstracts).
30. Wang L, Martin P, Blum KA, Kahl BS, Maeda LS, Advani R, Williams ME, Rule S, Rodriguez S, Pang C-F, Hedrick E, Goy A. The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial [abstract]. 53rd Annual Meeting of the American Society of Hematology: 2011 2011, Blood (ASH Annual Meeting Abstracts).
31. Wu T, Qin X, Kurepa Z, Kumar KR, Liu K, Kanta H, Zhou XJ, Satterthwaite AB, Davis LS, Mohan C. Shared signaling networks active in B cells isolated from genetically distinct mouse models of lupus. J Clin Invest 2007, 117:2186-2196. 10.1172/JCI30398, 1913486, 17641780.
32. Halcomb KE, Musuka S, Gutierrez T, Wright HL, Satterthwaite AB. Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells. Mol Immunol 2008, 46:233-241. 10.1016/j.molimm.2008.08.278, 2893544, 18849077.
33. Morel L, Croker BP, Blenman KR, Mohan C, Huang G, Gilkeson G, Wakeland EK. Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. Proc Natl Acad Sci USA 2000, 97:6670-6675. 10.1073/pnas.97.12.6670, 18697, 10841565.
34. Lo MS, Tsokos GC. Treatment of systemic lupus erythematosus: new advances in targeted therapy. Ann NY Acad Sci 2012, 1247:138-152. 10.1111/j.1749-6632.2011.06263.x, 22236448.
35. Kyttaris VC, Tsokos GC. Targeting lymphocyte signaling pathways as a therapeutic approach to systemic lupus erythematosus. Curr Opin Rheumatol 2011, 23:449-453. 10.1097/BOR.0b013e328349a242, 3158574, 21720246.
36. Deng GM, Liu L, Bahjat FR, Pine PR, Tsokos GC. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum 2010, 62:2086-2092. 2902591, 20222110.
37. Hardy RR, Hayakawa K, Parks DR, Herzenberg LA. Demonstration of B-cell maturation in X-linked immunodeficient mice by simultaneous three-colour immunofluorescence. Nature 1983, 306:270-272. 10.1038/306270a0, 6358897.
38. Kerner JD, Appleby MW, Mohr RN, Chien S, Rawlings DJ, Maliszewski CR, Witte ON, Perlmutter RM. Impaired expansion of mouse B cell progenitors lacking Btk. Immunity 1995, 3:301-312. 10.1016/1074-7613(95)90115-9, 7552995.
39. Sieckmann DG, Asofsky R, Mosier DE, Zitron IM, Paul WE. Activation of mouse lymphocytes by anti-immunoglobulin. I. Parameters of the proliferative response. J Exp Med 1978, 147:814-829. 10.1084/jem.147.3.814, 2184205, 416168.
40. Go NF, Castle BE, Barrett R, Kastelein R, Dang W, Mosmann TR, Moore KW, Howard M. Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med 1990, 172:1625-1631. 10.1084/jem.172.6.1625, 2188770, 2124252.
41. Miyake K, Yamashita Y, Hitoshi Y, Takatsu K, Kimoto M. Murine B cell proliferation and protection from apoptosis with an antibody against a 105-kD molecule: unresponsiveness of X-linked immunodeficient B cells. J Exp Med 1994, 180:1217-1224. 10.1084/jem.180.4.1217, 2191684, 7523567.
42. Santos-Argumedo L, Lund FE, Heath AW, Solvason N, Wu WW, Grimaldi JC, Parkhouse RM, Howard M. CD38 unresponsiveness of xid B cells implicates Bruton's tyrosine kinase (btk) as a regular of CD38 induced signal transduction. Int Immunol 1995, 7:163-170. 10.1093/intimm/7.2.163, 7734414.
43. Jefferies CA, Doyle S, Brunner C, Dunne A, Brint E, Wietek C, Walch E, Wirth T, O'Neill LA. Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4. J Biol Chem 2003, 278:26258-26264. 10.1074/jbc.M301484200, 12724322.
44. Satterthwaite AB, Cheroutre H, Khan WN, Sideras P, Witte ON. Btk dosage determines sensitivity to B cell antigen receptor cross-linking. Proc Natl Acad Sci USA 1997, 94:13152-13157. 10.1073/pnas.94.24.13152, 24278, 9371815.
45. Advani RH, Sharman JP, Smith SM, Boyd TE, Grant BW, Kolibaba KS, Furman RR, Buggy JJ, Loury DJ, Hedrick E, Izumi R, Hamdy AM, Fowler NH. The Btk Inhibitor Pci-32765 Is Highly Active and Well Tolerated in Patients (Pts) with Relapsed/Refractory B Cell Malignancies: Final Results from a Phase I Study. Annals of Oncology 2011, 22:135-135.
46. Vuyyuru R, Mohan C, Manser T, Rahman ZS. The lupus susceptibility locus Sle1 breaches peripheral B cell tolerance at the antibody-forming cell and germinal center checkpoints. J Immunol 2009, 183:5716-5727. 10.4049/jimmunol.0804215, 2879885, 19828626.
47. Gutierrez T, Halcomb KE, Coughran AJ, Li QZ, Satterthwaite AB. Separate checkpoints regulate splenic plasma cell accumulation and IgG autoantibody production in Lyn-deficient mice. Eur J Immunol 2010, 40:1897-1905. 10.1002/eji.200940043, 3057185, 20394076.
48. Kawakami Y, Inagaki N, Salek-Ardakani S, Kitaura J, Tanaka H, Nagao K, Xiao W, Nagai H, Croft M, Kawakami T. Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3. Proc Natl Acad Sci USA 2006, 103:153-158. 10.1073/pnas.0509784103, 1325006, 16371463.
49. Hata D, Kawakami Y, Inagaki N, Lantz CS, Kitamura T, Khan WN, Maeda-Yamamoto M, Miura T, Han W, Hartman SE, Yao L, Nagai H, Goldfeld AE, Alt FW, Galli SJ, Witte ON, Kawakami T. Involvement of Bruton's tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production. J Exp Med 1998, 187:1235-1247. 10.1084/jem.187.8.1235, 2212237, 9547335.
50. Heller F, Lindenmeyer MT, Cohen CD, Brandt U, Draganovici D, Fischereder M, Kretzler M, Anders HJ, Sitter T, Mosberger I, Kerjaschki D, Regele H, Schlondorff D, Segerer S. The contribution of B cells to renal interstitial inflammation. Am J Pathol 2007, 170:457-468. 10.2353/ajpath.2007.060554, 1851872, 17255314.
51. Segerer S, Schlondorff D. B cells and tertiary lymphoid organs in renal inflammation. Kidney Int 2008, 73:533-537. 10.1038/sj.ki.5002734, 18094677.
52. Renner B, Strassheim D, Amura CR, Kulik L, Ljubanovic D, Glogowska MJ, Takahashi K, Carroll MC, Holers VM, Thurman JM. B cell subsets contribute to renal injury and renal protection after ischemia/reperfusion. J Immunol 2010, 185:4393-4400. 10.4049/jimmunol.0903239, 3133676, 20810984.
53. Satterthwaite AB, Willis F, Kanchanastit P, Fruman D, Cantley LC, Helgason CD, Humphries RK, Lowell CA, Simon M, Leitges M, Tarakhovsky A, Tedder TF, Lesche R, Wu H, Witte ON. A sensitized genetic system for the analysis of murine B lymphocyte signal transduction pathways dependent on Bruton's tyrosine kinase. Proc Natl Acad Sci USA 2000, 97:6687-6692. 10.1073/pnas.110146697, 18703, 10829070.
54. Sasaki Y, Derudder E, Hobeika E, Pelanda R, Reth M, Rajewsky K, Schmidt-Supprian M. Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity 2006, 24:729-739. 10.1016/j.immuni.2006.04.005, 16782029.
55. Anderson JS, Teutsch M, Dong Z, Wortis HH. An essential role for Bruton's [corrected] tyrosine kinase in the regulation of B-cell apoptosis. Proc Natl Acad Sci USA 1996, 93:10966-10971. 10.1073/pnas.93.20.10966, 38267, 8855292.
56. Mangla A, Khare A, Vineeth V, Panday NN, Mukhopadhyay A, Ravindran B, Bal V, George A, Rath S. Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses. Blood 2004, 104:1191-1197. 10.1182/blood-2004-01-0207, 15117762.
57. Uckun F, Ozer Z, Vassilev A. Bruton's tyrosine kinase prevents activation of the anti-apoptotic transcription factor STAT3 and promotes apoptosis in neoplastic B-cells and B-cell precursors exposed to oxidative stress. Br J Haematol 2007, 136:574-589. 10.1111/j.1365-2141.2006.06468.x, 17367410.
58. Honda F, Kano H, Kanegane H, Nonoyama S, Kim ES, Lee SK, Takagi M, Mizutani S, Morio T. The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils. Nat Immunol 2012, 13:369-378. 10.1038/ni.2234, 22366891.